AZD0585 + AZD0585 placebo
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertriglyceridemia
Conditions
Hypertriglyceridemia
Trial Timeline
Jun 10, 2015 โ Mar 11, 2017
NCT ID
NCT02463071About AZD0585 + AZD0585 placebo
AZD0585 + AZD0585 placebo is a phase 3 stage product being developed by AstraZeneca for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02463071. Target conditions include Hypertriglyceridemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02463071 | Phase 3 | Completed |
Competing Products
20 competing products in Hypertriglyceridemia